Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M80,922Revenue $M6,932Net Margin (%)26.9Z-Score16.9
Enterprise Value $M79,943EPS $7.8Operating Margin %36.3F-Score8
P/E(ttm))38.0Cash Flow Per Share $7.4Pre-tax Margin (%)35.8Higher ROA y-yY
Price/Book8.510-y EBITDA Growth Rate %25.7Quick Ratio1.7Cash flow > EarningsY
Price/Sales9.75-y EBITDA Growth Rate %20.1Current Ratio2.1Lower Leverage y-yY
Price/Cash Flow20.5y-y EBITDA Growth Rate %43.7ROA % (ttm)15.7Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)21.6Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M237ROI % (ttm)19.7Gross Margin Increase y-yN

Gurus Latest Trades with BIIB

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BIIBRon Baron 2014-06-30 Add$274 - $320.13
($300.74)
$ 341.7314%Add 41.76%8,632
BIIBJoel Greenblatt 2014-06-30 Sold Out -0.02%$274 - $320.13
($300.74)
$ 341.7314%Sold Out0
BIIBGeorge Soros 2014-06-30 Sold Out -0.02%$274 - $320.13
($300.74)
$ 341.7314%Sold Out0
BIIBJohn Burbank 2014-06-30 Sold Out -0.01%$274 - $320.13
($300.74)
$ 341.7314%Sold Out0
BIIBGeorge Soros 2014-03-31 Buy 0.02%$273.518 - $351.94
($316.4)
$ 341.738%New holding, 7500 sh.7,500
BIIBJoel Greenblatt 2014-03-31 Buy 0.02%$273.518 - $351.94
($316.4)
$ 341.738%New holding, 3931 sh.3,931
BIIBRon Baron 2014-03-31 Buy 0.01%$273.518 - $351.94
($316.4)
$ 341.738%New holding, 6089 sh.6,089
BIIBJohn Burbank 2014-03-31 Buy 0.01%$273.518 - $351.94
($316.4)
$ 341.738%New holding, 783 sh.783
BIIBVanguard Health Care Fund 2014-03-31 Reduce-0.24%$273.518 - $351.94
($315.54)
$ 341.738%Reduce -32.19%599,400
BIIBRay Dalio 2014-03-31 Sold Out -0.04%$273.518 - $351.94
($316.4)
$ 341.738%Sold Out0
BIIBRay Dalio 2013-12-31 Add0.03%$223.85 - $295.88
($258.53)
$ 341.7332%Add 208.67%19,057
BIIBJohn Hussman 2013-12-31 Sold Out -0.99%$223.85 - $295.88
($258.53)
$ 341.7332%Sold Out0
BIIBVanguard Health Care Fund 2013-12-31 Reduce-0.47%$223.85 - $295.88
($258.53)
$ 341.7332%Reduce -39.09%884,000
BIIBJohn Hussman 2013-09-30 Add0.33%$206.53 - $248.13
($223.63)
$ 341.7353%Add 50%75,000
BIIBMario Gabelli 2013-09-30 Add$206.53 - $248.13
($223.63)
$ 341.7353%Add 81.87%3,310
BIIBRay Dalio 2013-09-30 Reduce-0.01%$206.53 - $248.13
($223.63)
$ 341.7353%Reduce -41.27%6,174
BIIBFrank Sands 2013-06-30 Add0.71%$192.77 - $240.86
($213.68)
$ 341.7360%Add 27.6%4,565,921
BIIBMario Gabelli 2013-06-30 Reduce$192.77 - $240.86
($213.68)
$ 341.7360%Reduce -25.1%1,820
BIIBJohn Hussman 2013-06-30 Reduce-1.45%$192.77 - $240.86
($213.68)
$ 341.7360%Reduce -80.62%50,000
BIIBPRIMECAP Management 2013-06-30 Reduce-0.28%$192.77 - $240.86
($213.68)
$ 341.7360%Reduce -5%18,246,809
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BIIB is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BIIB Ron Baron 2014-06-308,63200.01+41.76%
BIIB Mario Gabelli 2014-06-304,17500.01+16.46%
BIIB Frank Sands 2014-06-304,891,4632.063.9+0.38%
BIIB PRIMECAP Management 2014-06-3017,258,3117.286-1.39%
BIIB Vanguard Health Care Fund 2014-06-30559,7000.240.47-6.62%
BIIB George Soros 2014-06-30000Sold Out
BIIB Joel Greenblatt 2014-06-30000Sold Out
BIIB John Burbank 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


BIIB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SCANGOS GEORGE ACEO 2014-08-01Sell1,128$332.933.04view
SCANGOS GEORGE ACEO 2014-07-16Sell12,316$312.379.82view
Posner Brian SDirector 2014-06-20Sell605$3158.9view
Posner Brian SDirector 2014-06-13Sell700$310.510.48view
SCANGOS GEORGE ACEO 2014-06-02Sell484$318.937.56view
Holtzman Steven HEVP Corporate Development 2014-05-19Sell1,221$289.1518.64view
SCANGOS GEORGE ACEO 2014-05-01Sell2,123$285.5620.13view
Holtzman Steven HEVP Corporate Development 2014-04-17Sell1,221$29117.88view
PANGIA ROBERT WDirector 2014-04-01Sell6,250$308.4211.22view
SCANGOS GEORGE ACEO 2014-04-01Sell2,123$308.4211.22view

Press Releases about BIIB :

    Quarterly/Annual Reports about BIIB:

    News about BIIB:

    Articles On GuruFocus.com
    Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 
    Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
    Weekly 52-Week Highs Highlight: ORLY, LLL, BIIB, NVS Feb 09 2014 
    Weekly CFO Sells Highlight: CSOD, UTX, MEMS, SBAC, BIIB Sep 22 2013 
    PRIMECAP Trims Top Biotechs and More Aug 30 2013 
    Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
    52-Week High Guru Stocks: BIIB, GE, BDX, IR, PFE Sep 24 2012 
    Weekly Top Insider Sells: GOOG, FIS, ORCL, and BIIB Aug 06 2012 
    Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
    Bearish John Hussman Sold Heavily in the First Quarter; New Portfolio Update May 02 2012 


    More From Other Websites
    Biogen's Eloctate Approved in Canada for Hemophilia A Aug 27 2014
    Should you buy ISIS? No, not that one Aug 27 2014
    Celgene, Gilead Lead Big Biotech Stock Movers Aug 26 2014
    Biogen Idec in Panel at the Citi 9th Annual Biotech Conference Aug 26 2014
    Health Canada Approves Eloctate™, the First Therapy to Extend the Interval Between Prophylactic... Aug 26 2014
    Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub Aug 26 2014
    Health Canada Approves Eloctate™, the First Therapy to Extend the Interval Between Prophylactic... Aug 26 2014
    Stocks Hold Decent Gains; InterMune Deal Sparks Biotechs Aug 25 2014
    Majority Of IBD 50 Firms Strong On Sponsorship Aug 22 2014
    Data on Celgene's Revlimid Published in Oncology Journal Aug 22 2014
    Dell CIO Andi Karaboutis Leaving for Biotech Firm Biogen Aug 21 2014
    The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead Sciences, Amgen, Roche and... Aug 21 2014
    Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions Aug 21 2014
    6 Biotech Stocks to Buy Now With Up to 100% Upside Potential Aug 20 2014
    [video] Hottest stories not always hottest stock: Greenberg Aug 19 2014
    Want a better return than Apple or Google? Aug 19 2014
    Biogen Strengthens MS Portfolio with Plegridy FDA Approval Aug 19 2014
    Why Biogen Idec (BIIB) Stock Is Gaining Today Aug 18 2014
    Biogen Idec: Drug Approval Offers 'Underappreciated Earnings Upside," Morgan Stanley Says Aug 18 2014
    [video] Cramer: Market about Russia-Ukraine Aug 18 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK